Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 14/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6731055 | 0.94 | GRM2 (0.56) | GRM2CYP11B1GAAMMP1MMP9 | |
| SCHEMBL6767836 | 0.91 | GRM2 (0.71) | GRM2CYP11B1GAAPDE4APDE4B | |
| SCHEMBL6733757 | 0.86 | GRM2 (0.53) | GRM2 | |
| SCHEMBL6732511 | 0.86 | GRM2 (0.72) | GRM2 | |
| SCHEMBL6731078 | 0.84 | GRM2 (0.70) | GRM2 | |
| SCHEMBL6728012 | 0.83 | GRM2 (0.58) | GRM2 | |
| SCHEMBL6733077 | 0.83 | GRM2 (0.84) | GRM2 | |
| SCHEMBL6735500 | 0.83 | GRM2 (0.59) | GRM2 | |
| SCHEMBL6731488 | 0.83 | GRM2 (0.60) | GRM2 | |
| SCHEMBL6727795 | 0.82 | GRM2 (0.66) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6800651-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-10-05 | — | — | US | claimed |
| US-20040006114-A1 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | GRM1, GRIN1, GRM2 | GRM2 3/4885CYP11B1 989/4885GAA 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.